Immatics harnesses a suite of technology platforms matched with advanced biologic understanding to identify antigens which are highly specific to cancer cells, thereby delivering true targets: distinct molecular barcodes that identify tumor cells and that are not present on healthy cells. The resulting target resource gives the Immatics team a drug discovery advantage for the company’s own proprietary pipeline and for collaborations with world-leading industry partners.

Immatics expects to grow utilizing the knowledge and experience gained from the partnered programs to improve the development pathways for its proprietary programs.

Bristol Myers Squibb – Clinical Co-Development Collaboration

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401 (Focus on clinical development of TCR Bispecific program IMA401)

GSK – Research Collaboration

GSK and Immatics Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancer Indications (Focus on development of Adoptive Cell Therapies)

Bristol Myers Squibb – Research collaboration

Immatics and Bristol Myers Squibb, Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies (Focus on development of Adoptive Cell Therapies)

Genmab – Research collaboration

Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies (Focus on development of Bispecifics)

MDACC – Strategic partnership

Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies (Focus on clinical ACT development)

Contact us about
Partnering Opportunities

Business Development

E-Mail: partnering@immatics.com
Immatics Biotechnologies GmbH
Business Development Group
Machtlfinger Str. 11
81379 München